Abstract
A phase III trial of a new drug for the treatment of advanced breast cancer has shown that adding it to hormone therapy can lengthen time to disease progression and increase the chance of a tumour shrinking. Researchers at The Royal Marsden NHS Foundation Trust and the Institute of Cancer Research (ICR) enrolled 708 people […]
Full Text 
Sign-in/Register to access full text options
Sign-in/Register to access full text options 
Published version (
Free)
Free) 
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a call
